Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Summary

This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide (TMZ).

Timeline

Start

2020-02-11

Primary completion

2026-12-31

Completion

2026-12-31

Publications

• Nabors LB, Lamb LS, Goswami T, Rochlin K, Youngblood SL. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified gammadelta t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions. Front Immunol. 2024 Feb 7;15:1299044. doi: 10.3389/fimmu.2024.1299044. eCollection 2024.
• Zhao Y, Dong P, He W, Zhang J, Chen H. gammadelta T cells: Major advances in basic and clinical research in tumor immunotherapy. Chin Med J (Engl). 2024 Jan 5;137(1):21-33. doi: 10.1097/CM9.0000000000002781. Epub 2023 Aug 18.

Drugs

Indications